Invitrogen Divests German BioReliance Manufacturing Unit to Investor Group; Business Not Aligned With Invitrogen s Goals | GenomeWeb

This update serves to clarify that Invitrogen has divested the Heidelberg, Germany-based unit of its BioReliance business. The BioReliance business itself, which Invitrogen will retain, is based in Rockville, Md. The original story was based on a press release that did not describe the relationship between the Heidelberg and Rockville businesses.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.